ESSA Pharma Inc. (EPIX): Price and Financial Metrics
GET POWR RATINGS... FREE!
EPIX Stock Price Chart Interactive Chart >
EPIX Price/Volume Stats
| Current price | $2.90 | 52-week high | $8.03 |
| Prev. close | $3.00 | 52-week low | $1.40 |
| Day low | $2.86 | Volume | 26,900 |
| Day high | $3.00 | Avg. volume | 229,661 |
| 50-day MA | $2.97 | Dividend yield | N/A |
| 200-day MA | $2.92 | Market Cap | 127.87M |
ESSA Pharma Inc. (EPIX) Company Bio
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on the development of novel and proprietary therapies for the treatment of prostate cancer. Its product candidate is EPI-506, an oral small molecule pro-drug that is in Phase 1/2 clinical trial, which blocks the N-terminal domain of the androgen receptor. The company was founded in 2009 and is based in Vancouver, Canada.
Latest EPIX News From Around the Web
Below are the latest news stories about ESSA PHARMA INC that investors may wish to consider to help them evaluate EPIX as an investment opportunity.
ESSA Pharma to Present at the Oppenheimer 33rd Annual Healthcare ConferenceESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be presenting at the virtual Oppenheimer 33rd Annual Healthcare Conference on Wednesday, March 15, 2023, at 11:20 a.m. Eastern Time. |
ESSA Pharma Inc.'s (NASDAQ:EPIX) recent 12% pullback adds to one-year year losses, institutional owners may take drastic measuresKey Insights Institutions' substantial holdings in ESSA Pharma implies that they have significant influence over the... |
EPIX: Deep and Sustained PSA Responses in Phase 1/2 Combination Trial of EPI-7386 and Enzalutamide…By David Bautz, PhD NASDAQ:EPIX READ THE FULL EPIX RESEARCH REPORT Business Update Update on EPI-7386 Phase 1 Clinical Trials On February 13, 2023, ESSA Pharma Inc. (NASDAQ:EPIX) announced that updated data from two Phase 1 clinical trials of EPI-7386 in patients with metastatic castration-resistant prostate cancer (mCRPC) would be presented at the 2023 American Society of Clinical Oncology |
ESSA Pharma Announces Presentations at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU)ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that further analyses of initial clinical data from two Phase 1 studies of EPI-7386 in patients with metastatic castration-resistant prostate cancer ("mCRPC") will be presented at the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium ("ASCO GU"), taking place February 16-19, 2023, i |
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2022ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fiscal first quarter ended December 31, 2022. All references to "$" in this release refer to United States dollars, unless otherwise indicated. |
EPIX Price Returns
| 1-mo | -9.09% |
| 3-mo | N/A |
| 6-mo | 62.92% |
| 1-year | -53.90% |
| 3-year | -34.83% |
| 5-year | -19.44% |
| YTD | 15.08% |
| 2022 | -82.25% |
| 2021 | 19.03% |
| 2020 | 116.91% |
| 2019 | 161.90% |
| 2018 | -52.05% |
Loading social stream, please wait...